MAPT and Alzheimer disease: An exploratory analysis in the supporting information further indicates that higher plasma GFAP was only significantly associated with smaller hippocampus volume among individuals classified as p‐tau positive but not p‐tau negative (Figure S4, Table S4), which confirms GFAP's role in AD pathology versus normal aging.